Stephen Dilly sold $8.57M worth of shares in Aimmune Therapeutics, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.